This resource provides a patient-friendly overview of the ADSTILADRIN (nadofaragene firadenovec-vncg) clinical story as well as what patients should expect before and after treatment.
Access and download information and support tools for ADSTILADRIN
Getting Started With ADSTILADRIN for Patients
ADSTILADRIN Clinical Overview
This piece summarizes key information about ADSTILADRIN, including clinical data as well as dosing and support information.
Instructions for Use
These instructions include an overview of storage, preparation, administration, and disposal information for ADSTILADRIN.
Product Acquisition Leave Behind
This leave behind provides a high-level product overview of ADSTILADRIN, including product codes.
Medicare Part B Reimbursement Guide
This piece provides information about Medicare Part B reimbursement.
ADSTILADRIN in Practice
Learn from Neal Shore, MD, FACS, a clinician from the ADSTILADRIN clinical trials, about ordering, storage, dosing, preparation, administration, and follow-up appointments.
Hear From a Board-Certified Urologist
“In bladder oncology, I think that this represents a transformative breakthrough.”
ADSTILADRIN Offers a Unique Way to Treat NMIBC
ADSTILADRIN is a gene therapy. It delivers the human interferon alpha 2B (IFNα2b) gene to bladder urothelial cells. It does not alter any existing genes in the body like some other gene therapies.
Sign Up for Information
Sign up to receive information and updates on ADSTILADRIN
Important Safety Information
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.
WARNINGS AND PRECAUTIONS
- Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
- Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.
DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.
USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.
ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).
Please see full Prescribing Information for ADSTILADRIN.